Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-01-09
1999-09-07
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 13, 514 15, 514 16, 514903, 530324, 530325, 530326, 530327, 530328, 530329, A61K 3800
Patent
active
059487640
ABSTRACT:
The present invention is directed toward peptide analogues of human myelin basic protein for use in the treatment of multiple sclerosis. Within one aspect, peptide analogues suitable for treating multiple sclerosis are provided which are at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. In addition, such analogues may be altered from the native sequence at positions 87, 88, 97, 98 or 99 to a D-amino acid. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are also provided, as well as methods for treating multiple sclerosis.
REFERENCES:
HCAPLUS AN 1994:45950, Weiner et al., WO 9321222, (abstract) Oct. 28, 1993.
Rudinger S., Peptide Hormones, pp. 1-6, Jun. 1976.
Abstract 65027 from Biol. Abstr. 81(7):AB-701 (1985) of the article "Monoclonal antibodies to human myelin basic protein," by Chou et al., J. Neurochem. 46(1):47-53, 1985.
Acha-Orbea et al., "Limited Heterogeneity of T Cell Receptors from Lymphocytes Mediating Autoimmune Encephlomyelitis Allows Specific Immune Intervention," Cell 54: 263-273, 1988.
Babbitt et al., "Antigenic competition at the level of peptide-Ia binding," Proc. Natl. Acad. Aci. USA 83:4509-4513, 1986.
Bernard C., "Experimental Autoimmune Encephalomyelitis in Mice: Genetic Control of Susceptibility," Journal of Immunogenetics 3:263-274, 1976.
Brocke et al., "In Vitro Proliferative Responses and Antibody Titers Specific to Human Acetylcholine Receptor Synthetic Peptides in Patients with Myasthemia gravis and Relation to HLA Class II Genes," J. Clin. Invest. 82:1894-1900, 1988.
Brostoff and Howell, "T Cell Receptors, Immunoregulation and Autoimmunity," Clinical Immunology and Immunopathology, 62(1):1-7, 1992.
Carter and Rodriguez, "Immunosuppressive Treatment of Multiple Sclerosis," Mayo Clin. Proc. 64:664-669, 1989.
Chou et al., "Identity of Myelin Basic Protein from Multiple Sclerosis and Human Control Brains: Discovery of a Genetic Variant," Jounral of Neurochemistry, 30:745-750, 1978.
Day et al., "The Polyclonal Antibody Responses of Lewis Rats to the Synthetic Encephaloitogenic Neuropeptide S55S (Residues 72-84 of Guinea Pig Myelin Basic Protein) and Its Analogs," Journal of Neuroscience Research 18:214-221, 1987.
Einstein et al., "Suppression of Experimental Allergic Encephalomyelitis By Chemically Modified Encephalitogen," Ummunochemistry 9:1013-1019, 1972.
Evavold and Allen, "Separation of IL-4 Production from the Th Cell Proliferation by an Altered T Cell Receptor Ligand," Science 225:1308-1310, 1991.
Gammon et al., "Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation," Nature, 319:413-415, 1986.
Gaur et al., "Amelioration of Autoimmune Encephlomyelitis By a Nonimmunogenic Non-Self Peptide That Binds to I-A.sup.U," Journal of Immunology 148(10):3049-3054, 1992.
Gautam et al., "A Polyalanine Peptide with only Five Native Myelin Basic Protein Residues Induces Autoimmune Encephalomyelitis," J. Exp. Med. 176:605-609, 1992.
Gautam et al., "Inhibition of Experimental Autoimmune encephalomyelitis by Myelin Basic Protein Synthetic peptide-Induced Anergy," Science 258L 1491-1494, 1992.
Hadaen et al., "Thymic Hormones, Interleukins, Endotoxin and Thymomimetic Drugs in T Lymphocyte Ontogeny," in Advance in Immunopharmacology 3, L. Chedid et al. (Eds.), 1985, pp. 487-497.
Hashim and Day, "Synthetic Peptide Analogs to Probe the Immunological Expression of the Rat Encephalitogenic Neuropeptide," Journal of Neuroscience Research 18:209-213, 1987.
Hashim et al., "Suppression and Reversal of Allergic Encephalomyelitis in Guinea Pigs with a Non-Encephalotigenic Analogue of the Trytophan Region of the Myelin Basic Protein," Journal of Immunology 116(1): 126-130, 1976.
Hashim, G., "Experimental Allergic Encephalomyelitis: Activation of Suppressor T Lymphocytes By a Modified Sequence of the T Effector Determinant," Journal of Immunology 126(2):419-423, 1981.
Jahnke et al., "Sequence Homology Between Certain Viral Proteins and Proteins Related to Encephalomyelitis and Neuritis," Science 229:282-284, 1985.
Kardys and Hashim, "Experimental Allergic Encephalomyelitis in Lewis Rats: Immunoregulation of Disease-Inducing Determinant," Journal of Immunology 127(3):862-866, 1981.
Karin et al., "Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antogonism and Reduction of Interferon .gamma. and Tumor Necrosis Factor .beta. Production," J. Exp. Med. 180: 2227-2237, 1984.
Kira et al., "Experimental Allergic Encephalomyelitis in Rabbits. A Major Encephalitogenic Determinant within Residues 1-44 of Myelin Basic Protein," J. of Neuroimmunol. 12(3):183-193, 1986.
Kuchroo et al., "A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire," Journal of Immunology 153: 3326-3336, 1994.
Lamont et al., "Inhibition of Experimental Autoimmune Encephalomyelitis Induction In SJL/J Mice By Using A Peptide With High Affinity For IA.sup.S Molecules," Journal of Immunology 145(6):1687-1693, 1990.
Lehinger, A., "The Amino Acid Building Blocks of Proteins," in Biochemistry, 2.sup.nd ed., Worth Publishers, Inc. pp. 71-75, 1975.
Martin et al., "A Myelin Basic Protein Peptide Is Recognized by Cytotoixc T Cells in the Context of Four HLA-DR Types Associated with Multiple Sclerosis," Journal of Experimental Medicine 173:19-24, 1991.
Martin et al., "Diversity in Fine Specificity and T Cell Receptor Usage of the Human CD4.sup.+ Cytotoxic T Cell Response Specific for the Immunodominant Myelin Basic Protein Peptide 87-106," Journal of Immunology b148(5):1359-1366, 1992.
Martin et al., "Immunological Aspects of Demyelinating Disease," Annu. Rev. Immunol. 10:153-87, 1992.
Rothbard and Taylor, "A sequence pattern common to T cell eptiopes," EMBO J. 7(1):93-100, 1988.
Rothbard, J., "Peptides and Cellular Immune Response," Ann. Inst. Pasteur/Virologie 137 E:518-526, 1986.
Rudinger, J., "Characteristics of the amino acids as components of a peptide hormone sequence," in Peptide Hormones, J. A. Parsons (ed.), University Park Press, Baltimore, pp. 1-7, 1976.
Sakai et al., "Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins," Proc. Natl. Acad. Sci. USA 86:9470-9474, 1989.
Servis et al., "Two adjacent epitopes on a synthetic dodecapeptide induce lactate dehydrogenase B-specific helper and suppressor T cells," Proc. R. Soc. Lond. B 228:461-470, 1986.
Sette et al., "Analysis of lysozyme-specific immune responses by synthetic peptides. I. Characterization of antibody and T cell-mediated repsonses to the N-terminal peptide of hen egg-white lysozyme," Eur. J. Immunol. 16:1-6, 1986.
Smilek et al., "A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephlomyelitis," Proc. Natl. Acad. Sci. USA 88:9633-9637, 1991.
Sriram et al., "Administration of Myelin Basic Protein-coupled Spleen Cells Prevents Experimental Allergic Encephalitis," Cellular Immunology 75:378-382, 1983.
Steinman et al., "Natural occurence of thymocytes that react with myelin basic protein," Neurology 30(7):755-759, 1980.
Steinman et al., "Regulation of autosensitisation to encephalitogenic myelin basic protein by macrophage-associated and soluble antigen," Nature 265:173-175, 1977.
Steinman et al., "The Epigenetics of Multiple Sclerosis: Clues to Etiology and A Rational for Immune Therapy," Annu. Rev. Neuorsci. 17:247-265, 1994.
Su et al., "Synthetic Myelin basic Protein Peptide Analogs Are Specific Inhibitors of Phospholipid/Calcium-Dependent Protein Kinase (Protein Kinase C)," Biochemical and Biophysical Research Communications 134(1):78-84, 1986.
Talmadge et al., "Screening Models for Biological Response Modifiers," in 13.sup.th International Congress of Chemotherapy. Symposium, Biological Response Modifiers; SY 64 part 203, Vienna Aug. 28-Sep. 2, 1993, pp. 203/19-203/34.
Teitelbaum et
Conlon Paul J.
Gaur Amitabh
Ling Nicholas
Delacroix-Muirheid C.
Neurocrine Biosciences Inc.
Tsang Cecilia J.
LandOfFree
Methods for treatment of multiple sclerosis utilizing peptide an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of multiple sclerosis utilizing peptide an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of multiple sclerosis utilizing peptide an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804612